Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A collaborative study by the Lu and Ratcliffe research groups has found that the tumour-promoting immune microenvironment can be created by a deficiency in factor-inhibiting hypoxia-inducible factor (FIH).

Inhibition of hypoxia-inducible factor (HIF) is a recently approved cancer treatment strategy, and as such there is a pressing need to understand how regulators of HIF might affect tumour growth under physiological conditions. Professors Xin Lu and Peter Ratcliffe have collaborated to study factor-inhibiting HIF (FIH), an enzymatic inhibitor of HIF, to understand how it functions under physiological conditions.

Jingyi Ma and co-workers within the Lu and Ratcliffe research groups identify FIH as a key regulator of immune homeostasis and a suppressor of B cell lymphomagenesis throughout the physiological aging process. FIH deficiency in the host or in myeloid cells alone creates a tumour-supportive tumour microenvironment to promote cancer cell growth.

For more detail, please read the full paper in PNAS: /